Status:
COMPLETED
A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
Lead Sponsor:
Cell Genesys
Conditions:
Metastatic Pancreatic Cancer
Nonresectable Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To evaluate the safety and effectiveness of CG8020 and CG2505.
Detailed Description
To evaluate clinical and laboratory safety of CG 8020 and CG 2505 and to evaluate the efficacy of CG 8020 and CG 2505 as measured by clinical benefit response, progression-free survival, survival and ...
Eligibility Criteria
Inclusion
- Histologic or cytologic diagnosis of nonresectable or metastatic pancreatic adenocarcinoma
- Chemotherapy naïve or chemotherapy experienced pancreatic cancer
Exclusion
- Prior cancer vaccines or gene therapy
- History of clinically significant autoimmune disease (eg, systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis, glomerulonephritis, or vasculitis)
- History of another malignancy in the past five years, except adequately treated non-melanomatous skin cancer or superficial bladder cancer or carcinoma-in-situ of the cervix, unless approved by the Medical Monitor
Key Trial Info
Start Date :
June 1 2002
Trial Type :
INTERVENTIONAL
End Date :
June 1 2004
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00245362
Start Date
June 1 2002
End Date
June 1 2004
Last Update
October 28 2005
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
2
US Oncology
Dallas, Texas, United States